MICROBIX BIOSYSTEMS INC (MBX.CA) Stock Fundamental Analysis
Canada - Toronto Stock Exchange - TSX:MBX - CA59501P1045 - Common Stock
0.235 CAD
-0.01 (-2.08%)
We assign a fundamental rating of 4 out of 10 to MBX. MBX was compared to 22 industry peers in the Biotechnology industry. While MBX seems to be doing ok healthwise, there are quite some concerns on its profitability. MBX is not valued too expensively and it also shows a decent growth rate.
1. Profitability
1.1 Basic Checks
MBX had negative earnings in the past year.
MBX had a negative operating cash flow in the past year.
In multiple years MBX reported negative net income over the last 5 years.
The reported operating cash flow has been mixed in the past 5 years: MBX reported negative operating cash flow in multiple years.
1.2 Ratios
Looking at the Return On Assets, with a value of -6.00%, MBX belongs to the top of the industry, outperforming 90.91% of the companies in the same industry.
The Return On Equity of MBX (-8.08%) is better than 90.91% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -6% | ||
| ROE | -8.08% | ||
| ROIC | N/A |
ROA(3y)1.04%
ROA(5y)3.95%
ROE(3y)1.4%
ROE(5y)5.76%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
MBX has a better Gross Margin (53.02%) than 86.36% of its industry peers.
MBX's Gross Margin has improved in the last couple of years.
The Profit Margin and Operating Margin are not available for MBX so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 53.02% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.11%
GM growth 5Y3.66%
2. Health
2.1 Basic Checks
MBX does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, MBX has more shares outstanding
The number of shares outstanding for MBX has been increased compared to 5 years ago.
The debt/assets ratio for MBX is higher compared to a year ago.
2.2 Solvency
Based on the Altman-Z score of 1.73, we must say that MBX is in the distress zone and has some risk of bankruptcy.
With an excellent Altman-Z score value of 1.73, MBX belongs to the best of the industry, outperforming 81.82% of the companies in the same industry.
A Debt/Equity ratio of 0.24 indicates that MBX is not too dependend on debt financing.
MBX has a Debt to Equity ratio (0.24) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.24 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 1.73 |
ROIC/WACCN/A
WACC7.46%
2.3 Liquidity
A Current Ratio of 8.48 indicates that MBX has no problem at all paying its short term obligations.
With an excellent Current ratio value of 8.48, MBX belongs to the best of the industry, outperforming 90.91% of the companies in the same industry.
MBX has a Quick Ratio of 5.17. This indicates that MBX is financially healthy and has no problem in meeting its short term obligations.
MBX has a better Quick ratio (5.17) than 86.36% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 8.48 | ||
| Quick Ratio | 5.17 |
3. Growth
3.1 Past
MBX shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -163.28%.
MBX shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -26.81%.
Measured over the past years, MBX shows a quite strong growth in Revenue. The Revenue has been growing by 12.05% on average per year.
EPS 1Y (TTM)-163.28%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-440.62%
Revenue 1Y (TTM)-26.81%
Revenue growth 3Y-0.87%
Revenue growth 5Y12.05%
Sales Q2Q%-40.51%
3.2 Future
Based on estimates for the next years, MBX will show a very strong growth in Earnings Per Share. The EPS will grow by 52.75% on average per year.
Based on estimates for the next years, MBX will show a very strong growth in Revenue. The Revenue will grow by 29.96% on average per year.
EPS Next Y33.33%
EPS Next 2Y52.75%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year35.93%
Revenue Next 2Y29.96%
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
MBX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
The Price/Forward Earnings ratio is 5.82, which indicates a rather cheap valuation of MBX.
Based on the Price/Forward Earnings ratio, MBX is valued cheaper than 100.00% of the companies in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 23.70, MBX is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 5.82 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of MBX indicates a rather cheap valuation: MBX is cheaper than 95.45% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 142.69 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
MBX's earnings are expected to grow with 52.75% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y52.75%
EPS Next 3YN/A
5. Dividend
5.1 Amount
No dividends for MBX!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
TSX:MBX (1/8/2026, 7:00:00 PM)
0.235
-0.01 (-2.08%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners0.43%
Inst Owner ChangeN/A
Ins Owners14.76%
Ins Owner ChangeN/A
Market Cap32.66M
Revenue(TTM)18.59M
Net Income(TTM)-2.25M
Analysts80
Price Target0.51 (117.02%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-44.44%
PT rev (3m)-44.44%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 5.82 | ||
| P/S | 1.76 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 1.18 | ||
| P/tB | 1.36 | ||
| EV/EBITDA | 142.69 |
EPS(TTM)-0.02
EYN/A
EPS(NY)0.04
Fwd EY17.19%
FCF(TTM)-0.01
FCFYN/A
OCF(TTM)0
OCFYN/A
SpS0.13
BVpS0.2
TBVpS0.17
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -6% | ||
| ROE | -8.08% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 53.02% | ||
| FCFM | N/A |
ROA(3y)1.04%
ROA(5y)3.95%
ROE(3y)1.4%
ROE(5y)5.76%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.11%
GM growth 5Y3.66%
F-Score2
Asset Turnover0.5
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.24 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 34.25 | ||
| Cap/Depr | 44.81% | ||
| Cap/Sales | 4.29% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 8.48 | ||
| Quick Ratio | 5.17 | ||
| Altman-Z | 1.73 |
F-Score2
WACC7.46%
ROIC/WACCN/A
Cap/Depr(3y)83.66%
Cap/Depr(5y)119.48%
Cap/Sales(3y)5.99%
Cap/Sales(5y)7.06%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-163.28%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-440.62%
EPS Next Y33.33%
EPS Next 2Y52.75%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-26.81%
Revenue growth 3Y-0.87%
Revenue growth 5Y12.05%
Sales Q2Q%-40.51%
Revenue Next Year35.93%
Revenue Next 2Y29.96%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-139.08%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year4.01%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-135.95%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-101.85%
OCF growth 3YN/A
OCF growth 5YN/A
MICROBIX BIOSYSTEMS INC / MBX.CA FAQ
What is the ChartMill fundamental rating of MICROBIX BIOSYSTEMS INC (MBX.CA) stock?
ChartMill assigns a fundamental rating of 4 / 10 to MBX.CA.
What is the valuation status of MICROBIX BIOSYSTEMS INC (MBX.CA) stock?
ChartMill assigns a valuation rating of 5 / 10 to MICROBIX BIOSYSTEMS INC (MBX.CA). This can be considered as Fairly Valued.
What is the profitability of MBX stock?
MICROBIX BIOSYSTEMS INC (MBX.CA) has a profitability rating of 3 / 10.